# The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial

*PRI Rank #19 · Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/rank-19*

| Field | Value |
| --- | --- |
| Rank | #19 |
| 18m citations | 60 |
| Journal | Nature Medicine |
| Year | 2024 |
| DOI | 10.1038/s41591-024-03169-2 |
| Corresponding authors | Haifeng Zhang, Anthony Rosenzweig, Zhenhua Jia, Xinli Li |
| Institution | First Affiliated Hospital of Nanjing Medical University, China |

**Ranking page:** [Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026](https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026)

**Paper link:** [10.1038/s41591-024-03169-2](https://doi.org/10.1038/s41591-024-03169-2)

## Topics

Qiliqiangxin · traditional Chinese medicine · Heart failure with reduced ejection fraction · Heart failure with reduced ejection fraction · Natriuretic peptides · Left ventricular ejection fraction · Randomized controlled trial · Double-blind randomized controlled trial · Placebo-controlled trial · Heart failure hospitalization · Cardiovascular death · Composite Endpoint · Hazard ratio · Guideline-Directed Medical Therapy · All-Cause Mortality · Adverse events · Clinical outcomes · Multicenter trial · Cardiovascular death · Heart failure hospitalization

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```